Fred Alger Management LLC Increases Stake in Core Laboratories Inc. $CLB

Key Points

• Fred Alger Management LLC increased its holdings in Core Laboratories Inc. by 32.4%, now owning approximately 1.57% of the company, worth $11,045,000.
• Core Laboratories recently reported an EPS of $0.19, exceeding the consensus estimate, while revenue showed a slight decline of 0.3% year-over-year.
• The company announced a quarterly dividend of $0.01, representing an annualized dividend of $0.04 and a yield of 0.3%.

Fred Alger Management LLC boosted its stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 32.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 736,853 shares of the oil and gas company's stock after purchasing an additional 180,344 shares during the quarter. Fred Alger Management LLC owned about 1.57% of Core Laboratories worth $11,045,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in CLB. AlphaQuest LLC boosted its position in Core Laboratories by 265,800.0% during the first quarter. AlphaQuest LLC now owns 2,659 shares of the oil and gas company's stock valued at $40,000 after purchasing an additional 2,658 shares in the last quarter. Assetmark Inc. boosted its position in Core Laboratories by 92.5% during the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock valued at $43,000 after purchasing an additional 1,387 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Core Laboratories by 843.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock worth $57,000 after acquiring an additional 2,936 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Core Laboratories in the fourth quarter worth about $123,000. Finally, XTX Topco Ltd acquired a new stake in Core Laboratories in the first quarter worth about $155,000. Institutional investors own 97.81% of the company's stock.

Core Laboratories Stock Performance

Shares of Core Laboratories stock traded down $0.28 on Friday, reaching $12.39. 369,430 shares of the stock were exchanged, compared to its average volume of 465,440. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.47. Core Laboratories Inc. has a twelve month low of $9.72 and a twelve month high of $21.83. The firm has a market capitalization of $581.02 million, a price-to-earnings ratio of 19.98, a PEG ratio of 3.71 and a beta of 1.46. The business has a 50 day moving average price of $11.51 and a two-hundred day moving average price of $12.29.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.01. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.The firm had revenue of $130.16 million during the quarter, compared to the consensus estimate of $129.19 million. During the same quarter in the previous year, the company posted $0.22 earnings per share. The company's revenue was down .3% compared to the same quarter last year. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. Analysts anticipate that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 25th. Investors of record on Monday, August 4th were issued a dividend of $0.01 per share. The ex-dividend date of this dividend was Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. Core Laboratories's payout ratio is 6.45%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Zacks Research raised Core Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Finally, Stifel Nicolaus lowered their price target on Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Core Laboratories currently has a consensus rating of "Hold" and a consensus price target of $12.50.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.